Innate immunity and microbes: Conversations with the gut leading to intestinal tissue repair and fibrosis

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 8, Issue 3, 2009, Pages 228-247

  Gibson, Deanna L ^a   Montero, Marinieve ^a   Ryz, Natasha R ^a   Vallance, Bruce A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Citrobacter rodentium; Colitis; Dextran sodium sulfate; Fibrosis; IBD; Tissue repair; TLR

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; DEXTRAN SULFATE; IMIPENEM; INTERLEUKIN 11; INTERLEUKIN 6; METRONIDAZOLE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; NEOMYCIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; REGULATOR PROTEIN; SINGLE IMMUNOGLOBULIN INTERLEUKIN 1R RELATED PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIINFLAMMATORY ACTIVITY; BACTERIAL INFECTION; CITROBACTER RODENTIUM; COLITIS; CROHN DISEASE; DISEASE MODEL; ENTERITIS; GASTROINTESTINAL TRACT; HOST PATHOGEN INTERACTION; HUMAN; INNATE IMMUNITY; INTESTINAL FIBROSIS; INTESTINE EPITHELIUM; INTESTINE FLORA; INTESTINE MUCOSA; MICROBIAL ACTIVITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SALMONELLOSIS; TIGHT JUNCTION; TISSUE REPAIR;

EID: 73549094740     PISSN: 18715230     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152309789152002     Document Type: Review

References (187)

1. Savage, D. C. Microbial ecology of the gastrointestinal tract. Annu. Rev. Microbiol., 1977, 31, 107-133.
2. Hooper, L. V.; Gordon, J. I. Commensal host-bacterial relationships in the gut. Science, 2001, 292, 1115-1118.
3. Eckburg, P. B.; Bik, E. M.; Bernstein, C. N.; Purdom, E.; Dethlefsen, L.; Sargent, M.; Gill, S. R.; Nelson, K. E.; Relman, D. A. Diversity of the human intestinal microbial flora. Science, 2005, 308, 1635-1638.
4. Strober, W.; Fuss, I.; Mannon, P. The fundamental basis of inflammatory bowel disease. J. Clin. Invest., 2007, 117, 514-521.
5. Bouma, G.; Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol., 2003, 3, 521-533.
6. th ed.; Kleinman, R. E., Ed. PMPH: USA, 2008; vol. 1, p. 207.
7. Okayasu, I.; Hatakeyama, S.; Yamada, M.; Ohkusa, T.; Inagaki, Y.; Nakaya, R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology, 1990, 98, 694-702.
8. Kawada, M.; Arihiro, A.; Mizoguchi, E. Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J. Gastrointerol., 2007, 13, 5581-5593.
9. Cooper, H. S.; Murthy, S. N.; Shah, R. S.; Sedergran, D. J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest., 1993, 69, 238-249.
10. Dieleman, L. A.; Palmen, M. J.; Akol, H.; Bloemena, E.; Pena, A. S.; Meuwissen, S. G.; Van Rees, E. P. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol., 1998, 114, 385-391.
11. Dieleman, L. A.; Ridwan, B. U.; Tennyson, G. S.; Beagley, K. W.; Bucy, R. P.; Elson, C. O. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology, 1994, 107, 1643-1652.
12. Ni, J.; Chen, S. F.; Hollander, D. Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut, 1996, 39, 234-241.
13. Renes, I. B.; Verburg, M.; Van Nispen, D. J.; Taminiau, J. A.; Buller, H. A.; Dekker, J.; Einerhand, A. W. Epithelial proliferation, cell death, and gene expression in experimental colitis: alterations in carbonic anhydrase I, mucin MUC2, and trefoil factor 3 expression. Int. J. Colorectal Dis., 2002, 17, 317-326.
14. Vetuschi, A.; Latella, G.; Sferra, R.; Caprilli, R.; Gaudio, E. Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium-induced colitis in rats. Dig. Dis. Sci., 2002, 47, 1447-1457.
15. Tessner, T. G.; Cohn, S. M.; Schloemann, S.; Stenson, W. F. Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice. Gastroenterology, 1998, 115, 874-882.
16. Kitajima, S.; Takuma, S.; Morimoto, M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp. Anim., 1999, 48, 137-143.
17. Poritz, L. S.; Garver, K. I.; Green, C.; Fitzpatrick, L.; Ruggiero, F.; Koltun, W. A. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J. Surg. Res., 2007, 140, 12-19.
18. Ukena, S. N.; Singh, A.; Dringenberg, U.; Engelhardt, R.; Seidler, U.; Hansen, W.; Bleich, A.; Bruder, D.; Franzke, A.; Rogler, G.; Suerbaum, S.; Buer, J.; Gunzer, F.; Westendorf, A. M. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PloS ONE, 2007, 2, e1308.
19. Balda, M. S.; Matter, K. Tight junctions at a glance. J. Cell Sci., 2008, 121, 3677-3682.
20. Vetrano, S.; Correale, C.; Borroni, E. M.; Pagano, N.; Savino, B.; Locati, M.; Malesci, A.; Repici, A.; Danese, S. Colifagina, a novel preparation of 8 lysed bacteria ameliorates experimental colitis. Int. J. Immunopathol. Pharmacol., 2008, 21, 401-407.
21. Mennigen, R.; Nolte, K.; Rijcken, E.; Utech, M.; Loeffler, B.; Senninger, N.; Bruewer, M. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am. J. Physiol. Gastrointes. Liver Physiol., 2009, 296, G1140-9.
22. Heimesaat, M. M.; Fischer, A.; Siegmund, B.; Kupz, A.; Niebergall, J.; Fuchs, D.; Jahn, H. K.; Freudenberg, M.; Loddenkemper, C.; Batra, A.; Lehr, H. A.; Liesenfeld, O.; Blaut, M.; Gobel, U. B.; Schumann, R. R.; Bereswill, S. Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. PLoS ONE, 2007, 2, e662.
23. Nanda Kumar, N. S.; Balamurugan, R.; Jayakanthan, K.; Pulimood, A.; Pugazhendhi, S.; Ramakrishna, B. S. Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. J. Gastroenterol. Hepatol., 2008, 23, 1834-1839.
24. Ohkusa, T.; Yamada, M.; Takenaga, T.; Kitazume, C.; Yamamoto, N.; Sasabe, M.; Takashimizu, I.; Tamura, Y.; Sakamoto, E.; Kurosawa, H. Protective effect of metronidazole in experimental ulcerative colitis induced by dextran sulfate sodium. Nippon Shokakibyo Gakkai zasshi, 1987, 84, 2337-2346.
25. Hans, W.; Scholmerich, J.; Gross, V.; Falk, W. The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice. Eur. J. Gastroenterol. Hepatol., 2000, 12, 267-273.
26. Rath, H. C.; Schultz, M.; Freitag, R.; Dieleman, L. A.; Li, F.; Linde, H. J.; Scholmerich, J.; Sartor, R. B. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect. Immun., 2001, 69, 2277-2285.
27. Hudcovic, T.; Stepankova, R.; Cebra, J.; Tlaskalova-Hogenova, H. The role of microflora in the development of intestinal inflammation: acute and chronic colitis induced by dextran sulfate in germfree and conventionally reared immunocompetent and immunodeficient mice. Folia Microbiol., 2001, 46, 565-572.
28. Axelsson, L. G.; Midtvedts, T.; Bylund-Fellenius, A. C. The Role of Intestinal Bacteria, Bacterial Translocation and Endotoxin in Dextran Sodium Sulphate-Induced Colitis is the Mouse. Microb. Ecol. Health. Dis., 1996, 9, 225.
29. Bylund-Fellenius, A. C.; Landstromi, E.; Axelsson, L. G.; Midtvedt, T. Experimental colitis induced by dextran sulphate in normal and germfree mice. Microb. Ecol. Health. Dis., 1994, 7, 207.
30. Rakoff-Nahoum, S.; Paglino, J.; Eslami-Varzaneh, F.; Edberg, S.; Medzhitov, R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell, 2004, 118, 229-241.
31. Araki, Y.; Andoh, A.; Takizawa, J.; Takizawa, W.; Fujiyama, Y. Clostridium butyricum, a probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in rats. Int. J. Mol. Med., 2004, 13, 577-580.
32. Osman, N.; Adawi, D.; Ahrne, S.; Jeppsson, B.; Molin, G. Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Dig. Dis. Sci., 2004, 49, 320-327.
33. Rachmilewitz, D.; Katakura, K.; Karmeli, F.; Hayashi, T.; Reinus, C.; Rudensky, B.; Akira, S.; Takeda, K.; Lee, J.; Takabayashi, K.; Raz, E. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology, 2004, 126, 520-528.
34. Castagliuolo, I.; Galeazzi, F.; Ferrari, S.; Elli, M.; Brun, P.; Cavaggioni, A.; Tormen, D.; Sturniolo, G. C.; Morelli, L.; Palu, G. Beneficial effect of auto-aggregating Lactobacillus crispatus on experimentally induced colitis in mice. FEMS Immunol. Med. Microbiol., 2005, 43, 197-204.
35. Osman, N.; Adawi, D.; Molin, G.; Ahrne, S.; Berggren, A.; Jeppsson, B. Bifidobacterium infantis strains with and without a combination of oligofructose and inulin (OFI) attenuate inflammation in DSS-induced colitis in rats. BMC Gastro., 2006, 6, 31.
36. Kokesova, A.; Frolova, L.; Kverka, M.; Sokol, D.; Rossmann, P.; Bartova, J.; Tlaskalova-Hogenova, H. Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice. Folia Microbiol., 2006, 51, 478-484.
37. Geier, M. S.; Butler, R. N.; Giffard, P. M.; Howarth, G. S. Lactobacillus fermentum BR11, a potential new probiotic, alleviates symptoms of colitis induced by dextran sulfate sodium (DSS) in rats. Int. J. Food Microbiol., 2007, 114, 267-274.
38. Fitzpatrick, L. R.; Hertzog, K. L.; Quatse, A. L.; Koltun, W. A.; Small, J. S.; Vrana, K. Effects of the probiotic formulation VSL#3 on colitis in weanling rats. J. Pediatr. Gastroenterol. Nutr., 2007, 44, 561-570.
39. Chung, Y. W.; Choi, J. H.; Oh, T. Y.; Eun, C. S.; Han, D. S. Lactobacillus casei prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4 mutant mice. Clin. Exp. Immunol., 2008, 151, 182-189.
40. Lee, H. S.; Han, S. Y.; Bae, E. A.; Huh, C. S.; Ahn, Y. T.; Lee, J. H.; Kim, D. H. Lactic acid bacteria inhibit proinflammatory cytokine expression and bacterial glycosaminoglycan degradation activity in dextran sulfate sodium-induced colitic mice. Int. Immunopharmacol., 2008, 8, 574-580.
41. Fitzpatrick, L. R.; Small, J.; Hoerr, R. A.; Bostwick, E. F.; Maines, L.; Koltun, W. A. In vitro and in vivo effects of the probiotic Escherichia coli strain M-17: immunomodulation and attenuation of murine colitis. Br. J. Nutr., 2008, 100, 530-541.
42. Osman, N.; Adawi, D.; Ahrne, S.; Jeppsson, B.; Molin, G. Probiotics and blueberry attenuate the severity of dextran sulfate sodium (DSS)-induced colitis. Dig. Dis. Sci., 2008, 53, 2464-2473.
43. Chen, L. L.; Wang, X. H.; Cui, Y.; Lian, G. H.; Zhang, J.; Ouyang, C. H.; Lu, F. G. Therapeutic effects of four strains of probiotics on experimental colitis in mice. World. J. Gastro., 2009, 15, 321-327.
44. Fukuda, M.; Kanauchi, O.; Araki, Y.; Andoh, A.; Mitsuyama, K.; Takagi, K.; Toyonaga, A.; Sata, M.; Fujiyama, Y.; Fukuoka, M.; Matsumoto, Y.; Bamba, T. Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. Int. J. Mol. Med., 2002, 9, 65-70.
45. Schultz, M.; Strauch, U. G.; Linde, H. J.; Watzl, S.; Obermeier, F.; Gottl, C.; Dunger, N.; Grunwald, N.; Scholmerich, J.; Rath, H. C. Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin. Diagn. Lab. Immunol., 2004, 11, 372-378.
46. Herias, M. V.; Koninkx, J. F.; Vos, J. G.; Huis in't Veld, J. H.; van Dijk, J. E. Probiotic effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice. Int. J. Food Microbiol., 2005, 103, 143-155.
47. Gaudier, E.; Michel, C.; Segain, J. P.; Cherbut, C.; Hoebler, C. The VSL# 3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucus barrier in mice. J. Nutr., 2005, 135, 2753-2761.
48. Feighery, L. M.; Smith, P.; O'Mahony, L.; Fallon, P. G.; Brayden, D. J. Effects of Lactobacillus salivarius 433118 on intestinal inflammation, immunity status and in vitro colon function in two mouse models of inflammatory bowel disease. Dig. Dis. Sci., 2008, 53, 2495-2506.
49. Kamada, N.; Inoue, N.; Hisamatsu, T.; Okamoto, S.; Matsuoka, K.; Sato, T.; Chinen, H.; Hong, K. S.; Yamada, T.; Suzuki, Y.; Suzuki, T.; Watanabe, N.; Tsuchimoto, K.; Hibi, T. Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis. Inflamm. Bowel Dis., 2005, 11, 455-463.
50. Kawai, T.; Akira, S. TLR signaling. Semin. Immunol., 2007, 19, 24-32.
51. Stenson, W. F. Toll-like receptors and intestinal epithelial repair. Curr. Opin. Gastroenterol., 2008, 24, 103-107.
52. Chen, G.; Shaw, M. H.; Kim, Y. G.; Nunez, G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu. Rev. Pathol., 2009, 4, 365-398.
53. Canto, E.; Ricart, E.; Monfort, D.; Gonzalez-Juan, D.; Balanzo, J.; Rodriguez-Sanchez, J. L.; Vidal, S. TNF alpha production to TLR2 ligands in active IBD patients. Clin. Immunol., 2006, 119, 156-165.
54. Sartor, R. B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol., 2006, 3, 390-407.
55. Toiyama, Y.; Araki, T.; Yoshiyama, S.; Hiro, J.; Miki, C.; Kusunoki, M. The expression patterns of Toll-like receptors in the ileal pouch mucosa of postoperative ulcerative colitis patients. Surg. Today, 2006, 36, 287-290.
56. Watanabe, T.; Kitani, A.; Murray, P. J.; Wakatsuki, Y.; Fuss, I. J.; Strober, W. Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity, 2006, 25, 473-485.
57. Kawai, T.; Akira, S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol., 2009, 21, 317-337.
58. Araki, A.; Kanai, T.; Ishikura, T.; Makita, S.; Uraushihara, K.; Iiyama, R.; Totsuka, T.; Takeda, K.; Akira, S.; Watanabe, M. MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J. Gastroenterol., 2005, 40, 16-23.
59. Fukata, M.; Michelsen, K. S.; Eri, R.; Thomas, L. S.; Hu, B.; Lukasek, K.; Nast, C. C.; Lechago, J.; Xu, R.; Naiki, Y.; Soliman, A.; Arditi, M.; Abreu, M. T. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am. J. Physiol. Gastrointest. Liver Physiol., 2005, 288, G1055-65.
60. Masaki, T.; Chow, F.; Nikolic-Paterson, D. J.; Atkins, R. C.; Tesch, G. H. Heterogeneity of antigen expression explains controversy over glomerular macrophage accumulation in mouse glomerulonephritis. Nephrol. Dial. Transplant, 2003, 18, 178-181.
61. Cario, E.; Brown, D.; McKee, M.; Lynch-Devaney, K.; Gerken, G.; Podolsky, D. K. Commensal-associated molecular patterns induce selective toll-like receptor-trafficking from apical membrane to cytoplasmic compartments in polarized intestinal epithelium. Am. J. Pathol., 2002, 160, 165-173.
62. Ortega-Cava, C. F.; Ishihara, S.; Rumi, M. A.; Kawashima, K.; Ishimura, N.; Kazumori, H.; Udagawa, J.; Kadowaki, Y.; Kinoshita, Y. Strategic compartmentalization of Toll-like receptor 4 in the mouse gut. J. Immunol., 2003, 170, 3977-3985.
63. Ortega-Cava, C. F.; Ishihara, S.; Rumi, M. A.; Aziz, M. M.; Kazumori, H.; Yuki, T.; Mishima, Y.; Moriyama, I.; Kadota, C.; Oshima, N.; Amano, Y.; Kadowaki, Y.; Ishimura, N.; Kinoshita, Y. Epithelial toll-like receptor 5 is constitutively localized in the mouse cecum and exhibits distinctive down-regulation during experimental colitis. Clin. Vacc. Immunol., 2006, 13, 132-138.
64. Cario, E.; Gerken, G.; Podolsky, D. K. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology, 2007, 132, 1359-1374.
65. Albert, E. J.; Marshall, J. S. Aging in the absence of TLR2 is associated with reduced IFN-gamma responses in the large intestine and increased severity of induced colitis. J. Leukoc. Biol., 2008, 83, 833-842.
66. Lee, J.; Mo, J. H.; Katakura, K.; Alkalay, I.; Rucker, A. N.; Liu, Y. T.; Lee, H. K.; Shen, C.; Cojocaru, G.; Shenouda, S.; Kagnoff, M.; Eckmann, L.; Ben-Neriah, Y.; Raz, E. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat. Cell Biol., 2006, 8(12), 1327-1336.
67. Rhee, S. H.; Im, E.; Riegler, M.; Kokkotou, E.; O'Brien, M.; Pothoulakis, C. Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc. Natl. Acad. Sci. USA, 2005, 102, 13610-13615.
68. Podolsky, D. K.; Gerken, G.; Eyking, A.; Cario, E. Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology, 2009, 13, 209-220.
69. Taupin, D.; Podolsky, D. K. Trefoil factors: initiators of mucosal healing. Nat. Rev. Mol. Cell Biol., 2003, 4, 721-732.
70. Mashimo, H.; Wu, D. C.; Podolsky, D. K.; Fishman, M. C. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science, 1996, 274, 262-265.
71. Jerala, R. Structural biology of the LPS recognition. Int. Med. Microbiol., 2007, 297, 353-363.
72. Ungaro, R.; Fukata, M.; Hsu, D.; Hernandez, Y.; Breglio, K.; Chen, A.; Xu, R.; Sotolongo, J.; Espana, C.; Zaias, J.; Elson, G.; Mayer, L.; Kosco-Vilbois, M.; Abreu, M. T. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 296, G1167-1179.
73. Ohkawara, T.; Takeda, H.; Nishihira, J.; Miyashita, K.; Nihiwaki, M.; Ishiguro, Y.; Takeda, K.; Akira, S.; Iwanaga, T.; Sugiyama, T.; Asaka, M. Macrophage migration inhibitory factor contributes to the development of acute dextran sulphate sodium-induced colitis in Toll-like receptor 4 knockout mice. Clin. Exp. Immunol., 2005, 141, 412-421.
74. Fukata, M.; Chen, A.; Klepper, A.; Krishnareddy, S.; Vamadevan, A. S.; Thomas, L. S.; Xu, R.; Inoue, H.; Arditi, M.; Dannenberg, A. J.; Abreu, M. T. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastro., 2006, 131, 862-877.
75. Grabig, A.; Paclik, D.; Guzy, C.; Dankof, A.; Baumgart, D. C.; Erckenbrecht, J.; Raupach, B.; Sonnenborn, U.; Eckert, J.; Schumann, R. R.; Wiedenmann, B.; Dignass, A. U.; Sturm, A. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect. Immun., 2006, 74, 4075-4082.
76. Carvalho, F. A.; Barnich, N.; Sauvanet, P.; Darcha, C.; Gelot, A.; Darfeuille-Michaud, A. Crohn's disease-associated Escherichia coli LF82 aggravates colitis in injured mouse colon via signaling by flagellin. Inflamm. Bowel Dis., 2008, 14(8), 1051-1060.
77. Krieg, A. M.; Vollmer, J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol. Rev., 2007, 220, 251-269.
78. Rachmilewitz, D.; Karmeli, F.; Takabayashi, K.; Hayashi, T.; Leider-Trejo, L.; Lee, J.; Leoni, L. M.; Raz, E. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology, 2002, 122, 1428-1441.
79. Obermeier, F.; Dunger, N.; Deml, L.; Herfarth, H.; Scholmerich, J.; Falk, W. CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur. J. Immunol., 2002, 32, 2084-2092.
80. Obermeier, F.; Dunger, N.; Strauch, U. G.; Hofmann, C.; Bleich, A.; Grunwald, N.; Hedrich, H. J.; Aschenbrenner, E.; Schlegelberger, B.; Rogler, G.; Scholmerich, J.; Falk, W. CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. Gastroenterology, 2005, 129, 913-27.
81. Garlanda, C.; Riva, F.; Polentarutti, N.; Buracchi, C.; Sironi, M.; De Bortoli, M.; Muzio, M.; Bergottini, R.; Scanziani, E.; Vecchi, A.; Hirsch, E.; Mantovani, A. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc. Natl. Acad. Sci. USA, 2004, 101, 3522-3526.
82. Xiao, H.; Gulen, M. F.; Qin, J.; Yao, J.; Bulek, K.; Kish, D.; Altuntas, C. Z.; Wald, D.; Ma, C.; Zhou, H.; Tuohy, V. K.; Fairchild, R. L.; de la Motte, C.; Cua, D.; Vallance, B. A.; Li, X. The Tollinterleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity, 2007, 26, 461-475.
83. Garlanda, C.; Riva, F.; Veliz, T.; Polentarutti, N.; Pasqualini, F.; Radaelli, E.; Sironi, M.; Nebuloni, M.; Zorini, E. O.; Scanziani, E.; Mantovani, A. Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res., 2007, 67, 6017-6021.
84. Luperchio, S. A.; Schauer, D. B. Molecular pathogenesis of Citrobacter rodentium and transmissible murine colonic hyperplasia. Microbes Infect., 2001, 3, 333-340.
85. Ma, C.; Wickham, M. E.; Guttman, J. A.; Deng, W.; Walker, J.; Madsen, K. L.; Jacobson, K.; Vogl, W. A.; Finlay, B. B.; Vallance, B. A. Citrobacter rodentium infection causes both mitochondrial dysfunction and intestinal epithelial barrier disruption in vivo: role of mitochondrial associated protein (Map). Cell Microbiol., 2006, 8, 1669-1686.
86. Eckmann, L. Animal models of inflammatory bowel disease: lessons from enteric infections. Ann. NY Acad. Sci., 2006, 1072, 28-38.
87. Ishigame, H.; Kakuta, S.; Nagai, T.; Kadoki, M.; Nambu, A.; Komiyama, Y.; Fujikado, N.; Tanahashi, Y.; Akitsu, A.; Kotaki, H.; Sudo, K.; Nakae, S.; Sasakawa, C.; Iwakura, Y. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity, 2009, 30, 108-119.
88. Curtis, M. M.; Way, S. S. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology, 2009, 126, 177-85.
89. Gibson, D. L.; Ma, C.; Bergstrom, K. S.; Huang, J. T.; Man, C.; Vallance, B. A. MyD88 signalling plays a critical role in host defence by controlling pathogen burden and promoting epithelial cell homeostasis during Citrobacter rodentium-induced colitis. Cell Microbiol., 2008, 10, 618-631.
90. Gibson, D. L.; Ma, C.; Rosenberger, C. M.; Bergstrom, K. S.; Valdez, Y.; Huang, J. T.; Khan, M. A.; Vallance, B. A. Toll-like receptor 2 plays a critical role in maintaining mucosal integrity during Citrobacter rodentium-induced colitis. Cell Microbiol., 2008, 10, 388-403.
91. Cliffe, L. J.; Humphreys, N. E.; Lane, T. E.; Potten, C. S.; Booth, C.; Grencis, R. K. Accelerated intestinal epithelial cell turnover: a new mechanism of parasite expulsion. Science, 2005, 308, 1463-1465.
92. Brown, S. L.; Riehl, T. E.; Walker, M. R.; Geske, M. J.; Doherty, J. M.; Stenson, W. F.; Stappenbeck, T. S. Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J. Clin. Invest., 2007, 117, 258-269.
93. Wooten, R. M.; Ma, Y.; Yoder, R. A.; Brown, J. P.; Weis, J. H.; Zachary, J. F.; Kirschning, C. J.; Weis, J. J. Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi. J. Immunol., 2002, 168, 348-355.
94. Katz, J.; Zhang, P.; Martin, M.; Vogel, S. N.; Michalek, S. M. Tolllike receptor 2 is required for inflammatory responses to Francisella tularensis LVS. Infect. Immun., 2006, 74, 2809-2816.
95. Ozoren, N.; Masumoto, J.; Franchi, L.; Kanneganti, T. D.; Body-Malapel, M.; Erturk, I.; Jagirdar, R.; Zhu, L.; Inohara, N.; Bertin, J.; Coyle, A.; Grant, E. P.; Nunez, G. Distinct roles of TLR2 and the adaptor ASC in IL-1beta/IL-18 secretion in response to Listeria monocytogenes. J. Immunol., 2006, 176, 4337-4342.
96. Hausmann, M.; Kiessling, S.; Mestermann, S.; Webb, G.; Spottl, T.; Andus, T.; Scholmerich, J.; Herfarth, H.; Ray, K.; Falk, W.; Rogler, G. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology, 2002, 122, 1987-2000.
97. Melmed, G.; Thomas, L. S.; Lee, N.; Tesfay, S. Y.; Lukasek, K.; Michelsen, K. S.; Zhou, Y.; Hu, B.; Arditi, M.; Abreu, M. T. Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for hostmicrobial interactions in the gut. J. Immunol., 2003, 170, 1406-1415.
98. Su, L.; Shen, L.; Clayburgh, D. R.; Nalle, S. C.; Sullivan, E. A.; Meddings, J. B.; Abraham, C.; Turner, J. R. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology, 2009, 136, 551-563.
99. Uemura, T.; Nakayama, T.; Kusaba, T.; Yakata, Y.; Yamazumi, K.; Matsuu-Matsuyama, M.; Shichijo, K.; Sekine, I. The protective effect of interleukin-11 on the cell death induced by X-ray irradiation in cultured intestinal epithelial cell. J. Radiat. Res., 2007, 48, 171-177.
100. Boerma, M.; Wang, J.; Burnett, A. F.; Santin, A. D.; Roman, J. J.; Hauer-Jensen, M. Local administration of interleukin-11 ameliorates intestinal radiation injury in rats. Cancer Res., 2007, 67, 9501-9506.
101. Ropeleski, M. J.; Tang, J.; Walsh-Reitz, M. M.; Musch, M. W.; Chang, E. B. Interleukin-11-induced heat shock protein 25 confers intestinal epithelial-specific cytoprotection from oxidant stress. Gastroenterology, 2003, 124(5), 1358-1368.
102. Wang, R. J.; Peng, R. Y.; Gao, Y. B.; Chang, G. M.; Xu, X. P.; Fu, K. F.; Luo, Q. L. Jak/STAT signaling pathway of IL-11 in the protection of intestinal epithelial cells from neutron radiation. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2009, 25, 27-30.
103. Deutscher, N.; Bataille, F.; Hausmann, M.; Kiessling, S.; Muller-Newen, G.; Leeb, S. N.; Herfarth, H.; Heinrich, P. C.; Scholmerich, J.; Rogler, G. Functional expression of the interleukin-11 receptor alpha-chain in normal colonic epithelium and colon cancer. Int. J. Colorectal Dis., 2006, 21, 573-581.
104. Bamba, S.; Andoh, A.; Yasui, H.; Makino, J.; Kim, S.; Fujiyama, Y. Regulation of IL-11 expression in intestinal myofibroblasts: role of c-Jun AP-1- and MAPK-dependent pathways. Am. J. Physiol. Gastrointest. Liver Physiol., 2003, 285, G529-38.
105. Hoang, B.; Trinh, A.; Birnbaumer, L.; Edwards, R. A. Decreased MAPK- and PGE2-dependent IL-11 production in Gialpha2-/-colonic myofibroblasts. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 292, G1511-9.
106. Herrlinger, K. R.; Witthoeft, T.; Raedler, A.; Bokemeyer, B.; Krummenerl, T.; Schulzke, J. D.; Boerner, N.; Kueppers, B.; Emmrich, J.; Mescheder, A.; Schwertschlag, U.; Shapiro, M.; Stange, E. F. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am. J. Gastroenterol., 2006, 101, 793-7.
107. Sands, B. E.; Bank, S.; Sninsky, C. A.; Robinson, M.; Katz, S.; Singleton, J. W.; Miner, P. B.; Safdi, M. A.; Galandiuk, S.; Hanauer, S. B.; Varilek, G. W.; Buchman, A. L.; Rodgers, V. D.; Salzberg, B.; Cai, B.; Loewy, J.; DeBruin, M. F.; Rogge, H.; Shapiro, M.; Schwertschlag, U. S. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology, 1999, 117, 58-64.
108. Sands, B. E.; Winston, B. D.; Salzberg, B.; Safdi, M.; Barish, C.; Wruble, L.; Wilkins, R.; Shapiro, M.; Schwertschlag, U. S. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment. Pharmacol. Ther., 2002, 16, 399-406.
109. Dann, S. M.; Spehlmann, M. E.; Hammond, D. C.; Iimura, M.; Hase, K.; Choi, L. J.; Hanson, E.; Eckmann, L. IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens. J. Immunol., 2008, 180, 6816-6826.
110. Pierik, M.; Rutgeerts, P.; Vlietinck, R.; Vermeire, S. Pharmacogenetics in inflammatory bowel disease. World J. Gastroenterol., 2006, 12, 3657-3667.
111. Frolova, L.; Drastich, P.; Rossmann, P.; Klimesova, K.; Tlaskalova-Hogenova, H. Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis. J. Histochem. Cytochem., 2008, 56, 267-274.
112. Goncalves, N. S.; Ghaem-Maghami, M.; Monteleone, G.; Frankel, G.; Dougan, G.; Lewis, D. J.; Simmons, C. P.; MacDonald, T. T. Critical role for tumor necrosis factor alpha in controlling the number of lumenal pathogenic bacteria and immunopathology in infectious colitis. Infect. Immun., 2001, 69, 6651-6659.
113. Khan, M. A.; Ma, C.; Knodler, L. A.; Valdez, Y.; Rosenberger, C. M.; Deng, W.; Finlay, B. B.; Vallance, B. A. Toll-like receptor 4 contributes to colitis development but not to host defense during Citrobacter rodentium infection in mice. Infect. Immun., 2006, 74, 2522-2536.
114. Klein, E. J.; Stapp, J. R.; Clausen, C. R.; Boster, D. R.; Wells, J. G.; Qin, X.; Swerdlow, D. L.; Tarr, P. I. Shiga toxin-producing Escherichia coli in children with diarrhea: a prospective point-of-care study. J. Pediatr., 2002, 141, 172-177.
115. Murray, K. F.; Patterson, K. Escherichia coli O157:H7-induced hemolytic-uremic syndrome: histopathologic changes in the colon over time. Pediatr. Dev. Pathol., 2000, 3, 232-239.
116. Ng, S. C.; Kamm, M. A. Management of postoperative Crohn's disease. Am. J. Gastroenterol., 2008, 103, 1029-1035.
117. Regueiro, M. Management and prevention of postoperative Crohn's disease. Inflamm. Bowel Dis., 2009, [Epub ahead of print].
118. El-Hachem, S.; Regueiro, M. Postoperative Crohn's disease: prevention and treatment. Expert Rev. Gastroenterol. Hepatol., 2009, 3, 249-256.
119. Van Assche, G.; Geboes, K.; Rutgeerts, P. Medical therapy for Crohn's disease strictures. Inflamm. Bowel Dis., 2006, 10, 55-60.
120. Rutgeerts, P.; Geboes, K.; Vantrappen, G.; Beyls, J.; Kerremans, R.; Hiele, M. Predictability of the postoperative course of Crohn's disease. Gastroenterology, 1990, 99, 956-963.
121. Bucala, R.; Spiegel, L. A.; Chesney, J.; Hogan, M.; Cerami, A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1994, 1, 71-81.
122. Iwano, M.; Plieth, D.; Danoff, T. M.; Xue, C.; Okada, H.; Neilson, E. G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest., 2002, 110, 341-350.
123. Ivanova, L.; Butt, M. J.; Matsell, D. G. Mesenchymal transition in kidney collecting duct epithelial cells. Am. J. Physiol. Renal Physiol., 2008, 294, F1238-1248.
124. Rygiel, K. A.; Robertson, H.; Marshall, H. L.; Pekalski, M.; Zhao, L.; Booth, T. A.; Jones, D. E.; Burt, A. D.; Kirby, J. A. Epithelialmesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab. Invest. 2008, 88, 112-123.
125. Sempowski, G. D.; Chess, P. R.; Phipps, R. P. CD40 is a functional activation antigen and B7-independent T cell costimulatory molecule on normal human lung fibroblasts. J. Immunol., 1997, 158, 4670-4677.
126. Luzina, I. G.; Todd, N. W.; Iacono, A. T.; Atamas, S. P. Roles of T lymphocytes in pulmonary fibrosis. J. Leukoc. Biol., 2008, 83, 237-244.
127. Luzina, I. G.; Todd, N. W.; Nacu, N.; Lockatell, V.; Choi, J.; Hummers, L. K.; Atamas, S. P. Regulation of pulmonary inflammation and fibrosis through expression of integrins alphaVbeta3 and alphaVbeta5 on pulmonary T lymphocytes. Arthritis Rheum., 2009, 60, 1530-1539.
128. Mylonaki, M.; Rayment, N. B.; Rampton, D. S.; Hudspith, B. N.; Brostoff, J. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm. Bowel Dis., 2005, 11, 481-487.
129. Grassl, G. A.; Valdez, Y.; Bergstrom, K. S.; Vallance, B. A.; Finlay, B. B. Chronic enteric salmonella infection in mice leads to severe and persistent intestinal fibrosis. Gastroenterology, 2008, 134, 768-780.
130. Blumberg, R. S.; Saubermann, L. J.; Strober, W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr. Opin. Immunol., 1999, 11, 648-656.
131. De Winter, H.; Cheroutre, H.; Kronenberg, M. Mucosal immunity and inflammation. II. The yin and yang of T cells in intestinal inflammation: pathogenic and protective roles in a mouse colitis model. Am. J. Physiol., 1999, 276, G1317-1321.
132. Strober, W.; Fuss, I. J.; Blumberg, R. S. The immunology of mucosal models of inflammation. Annu. Rev. Immunol., 2002, 20, 495-549.
133. Eckburg, P. B.; Relman, D. A. The role of microbes in Crohn's disease. Clin. Infect. Dis., 2007, 44, 256-262.
134. Sartor, R. B.; Muehlbauer, M. Microbial host interactions in IBD: implications for pathogenesis and therapy. Curr. Gastroenterol. Rep., 2007, 9, 497-507.
135. De Jager, P. L.; Franchimont, D.; Waliszewska, A.; Bitton, A.; Cohen, A.; Langelier, D.; Belaiche, J.; Vermeire, S.; Farwell, L.; Goris, A.; Libioulle, C.; Jani, N.; Dassopoulos, T.; Bromfield, G. P.; Dubois, B.; Cho, J. H.; Brant, S. R.; Duerr, R. H.; Yang, H.; Rotter, J. I.; Silverberg, M. S.; Steinhart, A. H.; Daly, M. J.; Podolsky, D. K.; Louis, E.; Hafler, D. A.; Rioux, J. D. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun., 2007, 8, 387-397.
136. Browning, B. L.; Huebner, C.; Petermann, I.; Gearry, R. B.; Barclay, M. L.; Shelling, A. N.; Ferguson, L. R. Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am. J. Gastroenterol., 2007, 102, 2504-2512.
137. Targan, S. R.; Landers, C. J.; Yang, H.; Lodes, M. J.; Cong, Y.; Papadakis, K. A.; Vasiliauskas, E.; Elson, C. O.; Hershberg, R. M. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology, 2005, 128, 2020-2028.
138. Lodes, M. J.; Cong, Y.; Elson, C. O.; Mohamath, R.; Landers, C. J.; Targan, S. R.; Fort, M.; Hershberg, R. M. Bacterial flagellin is a dominant antigen in Crohn disease. J. Clin. Invest., 2004, 113, 1296-1306.
139. Cummings, J. R.; Cooney, R.; Pathan, S.; Anderson, C. A.; Barrett, J. C.; Beckly, J.; Geremia, A.; Hancock, L.; Guo, C.; Ahmad, T.; Cardon, L. R.; Jewell, D. P. Confirmation of the role of ATG16L1 as a Crohn's disease susceptibility gene. Inflamm. Bowel Dis.,2007, 13, 941-946.
140. Barrett, J. C.; Hansoul, S.; Nicolae, D. L.; Cho, J. H.; Duerr, R. H.; Rioux, J. D.; Brant, S. R.; Silverberg, M. S.; Taylor, K. D.; Barmada, M. M.; Bitton, A.; Dassopoulos, T.; Datta, L. W.; Green, T.; Griffiths, A. M.; Kistner, E. O.; Murtha, M. T.; Regueiro, M. D.; Rotter, J. I.; Schumm, L. P.; Steinhart, A. H.; Targan, S. R.; Xavier, R. J.; Libioulle, C.; Sandor, C.; Lathrop, M.; Belaiche, J.; Dewit, O.; Gut, I.; Heath, S.; Laukens, D.; Mni, M.; Rutgeerts, P.; Van Gossum, A.; Zelenika, D.; Franchimont, D.; Hugot, J. P.; de Vos, M.; Vermeire, S.; Louis, E.; Cardon, L. R.; Anderson, C. A.; Drummond, H.; Nimmo, E.; Ahmad, T.; Prescott, N. J.; Onnie, C. M.; Fisher, S. A.; Marchini, J.; Ghori, J.; Bumpstead, S.; Gwilliam, R.; Tremelling, M.; Deloukas, P.; Mansfield, J.; Jewell, D.; Satsangi, J.; Mathew, C. G.; Parkes, M.; Georges, M.; Daly, M. J. Genomewide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet., 2008, 40, 955-962.
141. Hugot, J. P.; Zaccaria, I.; Cavanaugh, J.; Yang, H.; Vermeire, S.; Lappalainen, M.; Schreiber, S.; Annese, V.; Jewell, D. P.; Fowler, E. V.; Brant, S. R.; Silverberg, M. S.; Cho, J.; Rioux, J. D.; Satsangi, J.; Parkes, M. Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am. J. Gastroenterol., 2007, 102, 1259-1267.
142. Ogura, Y.; Bonen, D. K.; Inohara, N.; Nicolae, D. L.; Chen, F. F.; Ramos, R.; Britton, H.; Moran, T.; Karaliuskas, R.; Duerr, R. H.; Achkar, J. P.; Brant, S. R.; Bayless, T. M.; Kirschner, B. S.; Hanauer, S. B.; Nunez, G.; Cho, J. H. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature, 2001, 411, 603-606.
143. Abreu, M. T. Nod2 in normal and abnormal intestinal immune function. Gastroenterology, 2005, 129, 1302-1304.
144. Mourelle, M.; Salas, A.; Guarner, F.; Crespo, E.; Garcia-Lafuente, A.; Malagelada, J. R. Stimulation of transforming growth factor beta1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology, 1998, 114, 519-526.
145. van Tol, E. A.; Petrusz, P.; Lund, P. K.; Yamauchi, M.; Sartor, R. B. Local production of corticotropin releasing hormone is increased in experimental intestinal inflammation in rats. Gut, 1996, 39, 385-392.
146. Otte, J. M.; Rosenberg, I. M.; Podolsky, D. K. Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology, 2003, 124, 1866-1878.
147. Walton, K. L.; Holt, L.; Sartor, R. B. Lipopolysaccharide activates innate immune responses in murine intestinal myofibroblasts through multiple signaling pathways. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 296, G601-611.
148. Seki, E.; De Minicis, S.; Osterreicher, C. H.; Kluwe, J.; Osawa, Y.; Brenner, D. A.; Schwabe, R. F. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med., 2007, 13, 1324-1332.
149. Leemans, J. C.; Butter, L. M.; Pulskens, W. P.; Teske, G. J.; Claessen, N.; van der Poll, T.; Florquin, S. The role of Toll-like receptor 2 in inflammation and fibrosis during progressive renal injury. PLoS One, 2009, 4, e5704.
150. Meneghin, A.; Choi, E. S.; Evanoff, H. L.; Kunkel, S. L.; Martinez, F. J.; Flaherty, K. R.; Toews, G. B.; Hogaboam, C. M. TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation. Histochem. Cell Biol., 2008, 130, 979-992.
151. Gabele, E.; Muhlbauer, M.; Dorn, C.; Weiss, T. S.; Froh, M.; Schnabl, B.; Wiest, R.; Scholmerich, J.; Obermeier, F.; Hellerbrand, C. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem. Biophys. Res. Commun., 2008, 376, 271-276.
152. Pucilowska, J. B.; Williams, K. L.; Lund, P. K. Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am. J. Physiol. Gastrointest. Liver Physiol., 2000, 279, G653-659.
153. Meneghin, A.; Hogaboam, C. M. Infectious disease, the innate immune response, and fibrosis. J. Clin. Invest., 2007, 117, 530-538.
154. Sartor, R. B. Induction of mucosal immune responses by bacteria and bacterial components. Curr. Opin. Gastroenterol., 2001, 17, 555-561.
155. Vallance, B. A.; Gunawan, M. I.; Hewlett, B.; Bercik, P.; Van Kampen, C.; Galeazzi, F.; Sime, P. J.; Gauldie, J.; Collins, S. M. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol., 2005, 289, G116-128.
156. Khan, W. I.; Motomura, Y.; Wang, H.; El-Sharkawy, R. T.; Verdu, E. F.; Verma-Gandhu, M.; Rollins, B. J.; Collins, S. M. Critical role of MCP-1 in the pathogenesis of experimental colitis in the context of immune and enterochromaffin cells. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 291, G803-811.
157. Neurath, M. F.; Fuss, I.; Kelsall, B. L.; Stuber, E.; Strober, W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med., 1995, 182, 1281-1290.
158. Lawrance, I. C.; Wu, F.; Leite, A. Z.; Willis, J.; West, G. A.; Fiocchi, C.; Chakravarti, S. A murine model of chronic inflammationinduced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology, 2003, 125, 1750-1761.
159. Coelho, A. L.; Hogaboam, C. M.; Kunkel, S. L. Chemokines provide the sustained inflammatory bridge between innate and acquired immunity. Cytokine Growth Factor Rev., 2005, 16, 553-560.
160. Sanchez-Munoz, F.; Dominguez-Lopez, A.; Yamamoto-Furusho, J. K. Role of cytokines in inflammatory bowel disease. World J. Gastrointerol., 2008, 14, 4280-4288.
161. Zimmerman, N. P.; Vongsa, R. A.; Wendt, M. K.; Dwinell, M. B. Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm. Bowel Dis., 2008, 14, 1000-1011.
162. McKaig, B. C.; Hughes, K.; Tighe, P. J.; Mahida, Y. R. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am. J. Physiol. Cell Physiol., 2002, 282, C172-182.
163. Leask, A.; Abraham, D. J. TGF-beta signaling and the fibrotic response. FASEB J., 2004, 18, 816-827.
164. Graham, M. F.; Bryson, G. R.; Diegelmann, R. F. Transforming growth factor beta 1 selectively augments collagen synthesis by human intestinal smooth muscle cells. Gastroenterology, 1990, 99, 447-453.
165. Stallmach, A.; Schuppan, D.; Riese, H. H.; Matthes, H.; Riecken, E. O. Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. Gastroenterology, 1992, 102, 1920-1929.
166. Clouthier, D. E.; Comerford, S. A.; Hammer, R. E. Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J. Clin. Invest., 1997, 100, 2697-2713.
167. Kitani, A.; Fuss, I. J.; Nakamura, K.; Schwartz, O. M.; Usui, T.; Strober, W. Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J. Exp. Med., 2000, 192, 41-52.
168. Leonard, E. J.; Yoshimura, T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol. Today, 1990, 11, 97-101.
169. Mukaida, N.; Harada, A.; Matsushima, K. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev., 1998, 9, 9-23.
170. Grimm, M. C.; Elsbury, S. K.; Pavli, P.; Doe, W. F. Enhanced expression and production of monocyte chemoattractant protein-1 in inflammatory bowel disease mucosa. J. Leukoc. Biol., 1996, 59, 804-812.
171. Mazzucchelli, L.; Hauser, C.; Zgraggen, K.; Wagner, H. E.; Hess, M. W.; Laissue, J. A.; Mueller, C. Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease. J. Pathol., 1996, 178, 201-206.
172. MacDermott, R. P.; Sanderson, I. R.; Reinecker, H. C. The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease. Inflamm. Bowel Dis., 1998, 4(1), 54-67.
173. Zhang, K.; Gharaee-Kermani, M.; Jones, M. L.; Warren, J. S.; Phan, S. H. Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis. J. Immunol., 1994, 153, 4733-4741.
174. Inoshima, I.; Kuwano, K.; Hamada, N.; Hagimoto, N.; Yoshimi, M.; Maeyama, T.; Takeshita, A.; Kitamoto, S.; Egashira, K.; Hara, N. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell Mol. Physiol., 2004, 286, L1038-44.
175. Lloyd, C. M.; Minto, A. W.; Dorf, M. E.; Proudfoot, A.; Wells, T. N.; Salant, D. J.; Gutierrez-Ramos, J.C. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J. Exp. Med., 1997, 185, 1371-1380.
176. Kitagawa, K.; Wada, T.; Furuichi, K.; Hashimoto, H.; Ishiwata, Y.; Asano, M.; Takeya, M.; Kuziel, W. A.; Matsushima, K.; Mukaida, N.; Yokoyama, H. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am. J. Pathol., 2004, 165, 237-246.
177. Marra, F.; DeFranco, R.; Grappone, C.; Milani, S.; Pastacaldi, S.; Pinzani, M.; Romanelli, R. G.; Laffi, G.; Gentilini, P. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am. J. Pathol., 1998, 152, 423-30.
178. Inoue, M.; Ino, Y.; Gibo, J.; Ito, T.; Hisano, T.; Arita, Y.; Nawata, H. The role of monocyte chemoattractant protein-1 in experimental chronic pancreatitis model induced by dibutyltin dichloride in rats. Pancreas, 2002, 25, e64-70.
179. Que, J. U.; Hentges, D. J. Effect of streptomycin administration on colonization resistance to Salmonella typhimurium in mice. Infect. Immun., 1985, 48, 169-174.
180. Barthel, M.; Hapfelmeier, S.; Quintanilla-Martinez, L.; Kremer, M.; Rohde, M.; Hogardt, M.; Pfeffer, K.; Russmann, H.; Hardt, W. D. Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host. Infect. Immun., 2003, 71, 2839-2858.
181. Zhang, Z.; Zheng, M.; Bindas, J.; Schwarzenberger, P.; Kolls, J. K. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm. Bowel Dis., 2006, 12, 382-388.
182. Fujino, S.; Andoh, A.; Bamba, S.; Ogawa, A.; Hata, K.; Araki, Y.; Bamba, T.; Fujiyama, Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut, 2003, 52, 65-70.
183. Chatfield, S. N.; Strahan, K.; Pickard, D.; Charles, I. G.; Hormaeche, C. E.; Dougan, G. Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model. Microb. Pathog., 1992, 12, 145-151.
184. O'Brien, A. D. Innate resistance of mice to Salmonella typhi infection. Infect. Immun., 1982, 38, 948-952.
185. Vazquez-Torres, A.; Vallance, B. A.; Bergman, M. A.; Finlay, B. B.; Cookson, B. T.; Jones-Carson, J.; Fang, F. C. Toll-like receptor 4 dependence of innate and adaptive immunity to Salmonella: importance of the Kupffer cell network. J. Immunol., 2004, 172, 6202-6208.
186. Bollrath, J.; Phesse, T. J.; von Burstin, V. A.; Putoczki, T.; Bennecke, M.; Bateman, T.; Nebelsiek, T.; Lundgren-May, T.; Canli, O.; Schwitalla, S.; Matthews, V.; Schmid, R. M.; Kirchner, T.; Arkan, M. C.; Ernst, M.; Greten, F. R. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell, 2009, 15, 91-102.
187. Sartor, R. B.; Cromartie, W. J.; Powell, D. W.; Schwab, J. H. Granulomatous enterocolitis induced in rats by purified bacterial cell wall fragments. Gastroenterology, 1985, 89, 587-595.